Nationwide Fund Advisors boosted its stake in Omnicell, Inc. (NASDAQ:OMCL) by 0.9% during the first quarter, according to its most recent filing with the SEC. The firm owned 253,955 shares of the company’s stock after buying an additional 2,224 shares during the period. Nationwide Fund Advisors owned approximately 0.69% of Omnicell worth $10,323,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Sei Investments Co. boosted its stake in shares of Omnicell by 165.3% in the third quarter. Sei Investments Co. now owns 4,229 shares of the company’s stock valued at $162,000 after buying an additional 2,635 shares in the last quarter. State of Alaska Department of Revenue boosted its stake in Omnicell by 3.0% in the first quarter. State of Alaska Department of Revenue now owns 4,080 shares of the company’s stock valued at $165,000 after buying an additional 120 shares during the period. Diversified Trust Co bought a new stake in Omnicell during the first quarter valued at approximately $228,000. Stephens Inc. AR boosted its stake in Omnicell by 26.3% in the third quarter. Stephens Inc. AR now owns 6,515 shares of the company’s stock valued at $250,000 after buying an additional 1,355 shares during the period. Finally, Municipal Employees Retirement System of Michigan boosted its stake in Omnicell by 1.7% in the third quarter. Municipal Employees Retirement System of Michigan now owns 7,970 shares of the company’s stock valued at $305,000 after buying an additional 130 shares during the period. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Shares of Omnicell, Inc. (NASDAQ:OMCL) traded down 0.307% during midday trading on Friday, hitting $40.625. 36,957 shares of the stock traded hands. The stock’s market capitalization is $1.51 billion. The firm has a 50-day moving average price of $40.71 and a 200-day moving average price of $36.78. Omnicell, Inc. has a 52 week low of $30.33 and a 52 week high of $42.35.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, May 4th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.30) by $0.36. The business had revenue of $150.90 million during the quarter, compared to analyst estimates of $152.63 million. Omnicell had a return on equity of 10.74% and a net margin of 1.24%. The company’s revenue for the quarter was down 12.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.35 earnings per share. On average, equities analysts predict that Omnicell, Inc. will post $1.28 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Nationwide Fund Advisors Buys 2,224 Shares of Omnicell, Inc. (OMCL)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/05/19/nationwide-fund-advisors-boosts-stake-in-omnicell-inc-omcl-updated.html.

Several brokerages recently weighed in on OMCL. Zacks Investment Research lowered shares of Omnicell from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. Oppenheimer Holdings Inc. restated an “outperform” rating and issued a $53.00 price objective (up from $43.00) on shares of Omnicell in a report on Tuesday, April 25th. Piper Jaffray Companies lowered shares of Omnicell from an “overweight” rating to a “neutral” rating and set a $40.00 price objective on the stock. in a report on Friday, April 21st. CIBC increased their target price on shares of Omnicell from $43.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday, April 26th. Finally, TheStreet upgraded shares of Omnicell from a “c” rating to a “b-” rating in a report on Wednesday, February 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $45.89.

In other Omnicell news, VP J Christopher Drew sold 10,625 shares of the business’s stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $40.97, for a total value of $435,306.25. Following the completion of the transaction, the vice president now owns 152,057 shares of the company’s stock, valued at approximately $6,229,775.29. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gary S. Petersmeyer sold 2,658 shares of the business’s stock in a transaction dated Friday, March 10th. The shares were sold at an average price of $37.45, for a total value of $99,542.10. Following the sale, the director now owns 20,085 shares of the company’s stock, valued at $752,183.25. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,926 shares of company stock valued at $1,412,089. 3.75% of the stock is owned by insiders.

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

5 Day Chart for NASDAQ:OMCL

Receive News & Stock Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related stocks with our FREE daily email newsletter.